{
  "id": 10793616,
  "title": "Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue",
  "url": "https://urgent.news/2026/09/29/merck-scibrunch-launch-up-to-2-13b-collaboration-to-develop",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T22:01:43.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/cancer/merck-scibrunch-launch-up-to-2-13b-collaboration-to-develop-preclinical-kras-inhibiting-molecular-glue/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Merck & Co. has entered into a collaboration deal with SciBrunch Therapeutics to develop, manufacture, and commercialize SciBrunch's preclinical oral precision cancer candidate, SPR2015. This collaboration could potentially generate up to $2.13 billion for SciBrunch. SPR2015 is a KRAS G12D (ON) inhibitor, which is a mutation found in various forms of cancer including colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The mutation leaves KRAS active and continuously signaling for cell proliferation and survival. Preclinical studies have shown that SPR2015 has nanomolar antiproliferative activities in various KRAS G12D-mutant cell lines while maintaining good selectivity over KRAS wildtype cells. In a head-to-head mouse study, SPR2015 demonstrated superior efficacy in CRC xenograft models compared to another unspecified G12D (ON) inhibitor. Merck and SciBrunch did not provide further details on the specifics of the collaboration.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}